Skip to main content
Print Save

Ixinity FDA Approval History

FDA Approved: Yes (First approved April 29, 2015)
Brand name: Ixinity
Generic name: coagulation factor IX (recombinant)
Company: Emergent BioSolutions Inc.
Treatment for: Hemophilia B

Ixinity (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.

Development timeline for Ixinity

DateArticle
Apr 30, 2015Approval Emergent BioSolutions Announces FDA Approval of Ixinity [coagulation factor IX (recombinant)] for Hemophilia B
Apr 18, 2012Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B

See also

Ixinity (coagulation factor IX (recombinant)) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer